Current evidence from large cardiovascular outcome trials provides reassurance that this modest chronotropic effect does not translate into increased cardiovascular risk for most patients
Obesity pills, which are now in development, could increase access and lower prices furtherespecially as the big companies jockey to gain market share in advance of their approval
Concerns are evident: 70% worry about long-term effects, while 66% are anxious about short-term ones
Importantly, the reduction in LBM was modest relative to the overall BW loss, suggesting that GLP-1 RAs favor selective adipose tissue reduction over loss of lean tissue
For more information: To view or add a comment, sign in The first Medicare Maximum Fair Prices took effect in January
GLP-1 and other weight-loss drugs have accelerated the trend we have been seeing in recent years with more educated consumers looking for nutritional products that fit their exact situation, a spokesperson for Arla says